Results 61 to 70 of about 4,730,542 (305)
The Economics of Cardiac Failure [PDF]
Journal of the Royal Society of Medicine, 1996 Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasingly important. Not only high technology applications have to be investigated, but also relatively cheap but very common strategies for diagnostic work up and therapy. This may yield major savings.
openaire +3 more sources
Cardiac-resynchronization therapy for the prevention of heart-failure events.
New England Journal of Medicine, 2009 BACKGROUND This trial was designed to determine whether cardiac-resynchronization therapy (CRT) with biventricular pacing would reduce the risk of death or heart-failure events in patients with mild cardiac symptoms, a reduced ejection fraction, and a ...
A. Moss +13 more
semanticscholar +1 more source
Journal of Cardiothoracic SurgeryBackground Acute ischemic mitral regurgitation (AIMR) is a significant complication of acute coronary syndrome that leads to severe and immediate hemodynamic deterioration and cardiogenic shock.
Ioana Dumitru +6 more
doaj +1 more source
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
Scientific Reports, 2022 Left ventricular (LV) remodeling after myocardial infarction (MI) is promoted by an intense fibrotic response, which could be targeted by the anti-fibrotic drug pirfenidone.
Alberto Aimo +8 more
doaj +1 more source
The interpretation of brain natriuretic peptide in critical care patients; will it ever be useful? [PDF]
, 2010 The measurement of B-type natriuretic peptide (BNP) is recommended for the diagnosis of decompensated heart failure, the prognosis of chronic heart failure is worse if BNP is increased and studies suggest that BNP is useful to guide therapy.
Dixon, J, Philips, B
core +2 more sources
Cardiac impairment or heart failure? [PDF]
BMJ, 2005 “There is no disease that you either have or don't have—except perhaps sudden death or rabies. All other diseases you either have a little or a lot of,” said Geoffrey Rose.1 This is true of “heart failure”—everybody can have a bit if they try hard enough, by physical exertion or even by emotional shock.2 But, apart from transient induced cardiac ...
Lehman, R, Doust, J, Glasziou, P
openaire +4 more sources
Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2019 H eart failure is one of the leading causes of death worldwide and has been singled out as an emerging epidemic. With a 5-year survival rate of 50%, heart failure poses a tremendous burden on our economic and healthcare system.
D. H. Tran, Zhao V. Wang
semanticscholar +1 more source
Pulmonary Circulation, 2022 Periodic repetition of right heart catheterization (RHC) in pulmonary arterial hypertension (PAH) can be challenging. We evaluated the correlation between RHC and cardiopulmonary exercise test (CPET) aiming at CPET use as a potential noninvasive tool for
B. Pezzuto +11 more
doaj +1 more source
Treatment of cardiomyopathy with PAP therapy in a patient with severe obstructive sleep apnea. [PDF]
, 2012 Obstructive sleep apnea is common in patients with heart failure. This case illustrates that treatment with PAP therapy can improve cardiac function in patients with both conditions.
Grewal, MD, Ritu G.
core +2 more sources
Journal of Medical Case Reports, 2019 Introduction Berlin Heart EXCOR® pediatric ventricular assist device is a mechanical circulatory support device currently used in pediatric patients. Sotos syndrome is a well-described multiple anomaly syndrome characterized by overgrowth, distinctive ...
Rita Gravino +8 more
doaj +1 more source